HC0301, an Innovative Small Nucleic Acid Drug Developed by Haichang Bio, Receives FDA Clearance for Phase II Clinical Trial in Advanced Hepatocellular Carcinoma

Feb 18, 2024 16:20 CST Updated 16:20

Haichang Biotech

Innovative Formulation Developer

Recently, Haichang Biotech announced that its self-developedInnovative Small Nucleic Acid Drug HC0301Has received the FDA's Phase II clinical trial approval by default and will be initiated at the Marlene and Stewart Greenebaum Cancer Center, targetingInternational Multicenter Clinical Study on Advanced Hepatocellular Carcinoma。

Previously, the Phase I dose-escalation clinical trial data of HC0301 for advanced solid tumors indicated itsGood safety profile, andGranted Orphan Drug Designation by the FDA.

About HC0301

HC0301 isHaichang Biotech Successfully Utilizes Its Self-Developed QTsomeTM Nucleic Acid Delivery TechnologyWillAntisense OligonucleotideArchexin is encapsulated within lipid nanoparticles to develop a novel AKT-1 inhibitor.This technology aims to alter the pharmacokinetic process of Archexin in vivo, optimizing the efficiency and precision of drug delivery, thereby enhancing its therapeutic effects. AKT-1 is a protein highly expressed in various solid tumors, closely related to tumor proliferation, survival, angiogenesis, and immune resistance, making it an important target for cancer treatment. HC0301 can specifically bind to AKT-1 mRNA, subsequently reducing AKT-1 protein expression. This unique mechanism demonstrates significant potential and value in anti-tumor therapy, offering broad developmental prospects for future research and treatment.

Source: Haichang Biotech

E.N.D

In order to allow everyone to learn and communicate with each other better,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。